Skip to main content

Table 1 Patient sample by IBD type

From: Implementing electronic patient reported outcomes in inflammatory bowel disease: patient participation, score reliability and validity

Patient characteristics

CD n = 6917

UC n = 6118

Unclassified n = 553

Total N = 13,588

P

Years in IBD registrya

Median (Min–Max)

25th; 75th percentiles

9 (0–19)

4; 15

11 (0–19)

5; 17

8 (0–19)

4; 13

10 (0–19)

5; 15

 < 0.001

Age: Mean (SD)Median (Min–Max)

Median (Min–Max)

25th;75th percentiles

45.9 (15.9) 44.7 (19–100)

33.0; 56.4

52.1 (16.7) 51.2 (19–101)

39.4; 64.3

51.5 (18.0) 49.8 (19–102)

37.0; 64.5

48.9 (16.6) 47.8 (19–102)

35.7; 60.7

 < 0.001

Age groups:

    

 < 0.001

 18–45

3512 (50.8)

2155 (35.2)

206 (37.3)

5873 (43.2)

  > 45–65

2422 (35.0)

2493 (40.8)

212 (38.3)

5127 (37.7)

 Over 65

983 (14.2)

1470 (24.0)

135 (24.4)

2588 (19.1)

Sex:

    

 < 0.001

 Female

3381 (48.9)

3167 (51.8)

315 (57.0)

6863 (50.5)

 Male

3536 (51.1)

2951 (48.2)

238 (43.0)

6725 (49.5)

Biologic treatmentb

    

 < 0.001

 Yes

2538 (36.7)

742 (12.1)

88 (15.9)

3368 (24.8)

 No (never)

4379 (63.3)

5376 (87.9)

465 (84.1)

10,220 (75.2)

SES

    

0.769

 1 to 5 (low)

1685 (24.4)

1443 (23.6)

132 (23.9)

3260 (24.0)

 6 to 7 (moderate)

2610 (37.7)

2355 (38.5)

211 (38.2)

5176 (38.2)

 8 to 10 (high)

2606 (37.7)

2305 (37.7)

207 (37.4)

5118 (37.8)

 Missing

16 (0.2)

15 (0.2)

3 (0.5)

34 (0.9)

  1. Values are n (column %) unless noted otherwise. P-values for statistically significant differences were estimated using Chi-square tests for comparisons of categorical data and analysis of variance for comparisons of continuous data
  2. aYear of inclusion in the IBD registry at the start of 2019. Zero represents less than 1 year within the registry
  3. bBiologic and small molecules treatment was defined as having purchased at least one biologic medication including: Vedolizumab, Infliximab, Adalimumab, Ustekinumab, Golimumab, Tofacitinib, or Certolizumab
  4. CD Crohn's disease; UC Ulcerative Colitis; IQR inter quartile range; SD standard deviation; SES socioeconomic status